Last reviewed · How we verify

Seroquel XR adjunctive

Inje University · FDA-approved active Small molecule Quality 5/100

Seroquel XR adjunctive is a Small molecule drug developed by Inje University. It is currently FDA-approved. Also known as: Seroquel XR, quetiapine XR, quetiapine.

Seroquel XR adjunctive is a marketed drug by Inje University, positioned in the psychiatric medication market with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and long-term patient use. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameSeroquel XR adjunctive
Also known asSeroquel XR, quetiapine XR, quetiapine
SponsorInje University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Seroquel XR adjunctive

What is Seroquel XR adjunctive?

Seroquel XR adjunctive is a Small molecule drug developed by Inje University.

Who makes Seroquel XR adjunctive?

Seroquel XR adjunctive is developed and marketed by Inje University (see full Inje University pipeline at /company/inje-university).

Is Seroquel XR adjunctive also known as anything else?

Seroquel XR adjunctive is also known as Seroquel XR, quetiapine XR, quetiapine.

What development phase is Seroquel XR adjunctive in?

Seroquel XR adjunctive is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing